E Sinanovic1, L Ramma1, A Vassall2, V Azevedo3, L Wilkinson4, N Ndjeka5, K McCarthy6, G Churchyard6, H Cox7. 1. Health Economics Unit, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa. 2. London School of Hygiene & Tropical Medicine, London, UK. 3. City Health, Cape Town Metro, South Africa. 4. Médecins Sans Frontières, Khayelitsha, South Africa. 5. TB Cluster, National Department of Health, Pretoria, South Africa. 6. Aurum Institute, Johannesburg, South Africa. 7. Division of Medical Microbiology and Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Abstract
SETTING: The cost of multidrug-resistant tuberculosis (MDR-TB) treatment is a major barrier to treatment scale-up in South Africa. OBJECTIVE: To estimate and compare the cost of treatment for rifampicin-resistant tuberculosis (RR-TB) in South Africa in different models of care in different settings. DESIGN: We estimated the costs of different models of care with varying levels of hospitalisation. These costs were used to calculate the total cost of treating all diagnosed cases of RR-TB in South Africa, and to estimate the budget impact of adopting a fully or partially decentralised model vs. a fully hospitalised model. RESULTS: The fully hospitalised model was 42% more costly than the fully decentralised model (US$13,432 vs. US$7753 per patient). A much shorter hospital stay in the decentralised models of care (44-57 days), compared to 128 days of hospitalisation in the fully hospitalised model, was the key contributor to the reduced cost of treatment. The annual total cost of treating all diagnosed cases ranged from US$110 million in the fully decentralised model to US$190 million in the fully hospitalised model. CONCLUSION: Following a more decentralised approach for treating RR-TB patients could potentially improve the affordability of RR-TB treatment in South Africa.
SETTING: The cost of multidrug-resistant tuberculosis (MDR-TB) treatment is a major barrier to treatment scale-up in South Africa. OBJECTIVE: To estimate and compare the cost of treatment for rifampicin-resistant tuberculosis (RR-TB) in South Africa in different models of care in different settings. DESIGN: We estimated the costs of different models of care with varying levels of hospitalisation. These costs were used to calculate the total cost of treating all diagnosed cases of RR-TB in South Africa, and to estimate the budget impact of adopting a fully or partially decentralised model vs. a fully hospitalised model. RESULTS: The fully hospitalised model was 42% more costly than the fully decentralised model (US$13,432 vs. US$7753 per patient). A much shorter hospital stay in the decentralised models of care (44-57 days), compared to 128 days of hospitalisation in the fully hospitalised model, was the key contributor to the reduced cost of treatment. The annual total cost of treating all diagnosed cases ranged from US$110 million in the fully decentralised model to US$190 million in the fully hospitalised model. CONCLUSION: Following a more decentralised approach for treating RR-TBpatients could potentially improve the affordability of RR-TB treatment in South Africa.
Authors: J C M Brust; N S Shah; M Scott; K Chaiyachati; M Lygizos; T L van der Merwe; S Bamber; Z Radebe; M Loveday; A P Moll; B Margot; U G Lalloo; G H Friedland; N R Gandhi Journal: Int J Tuberc Lung Dis Date: 2012-06-05 Impact factor: 2.373
Authors: H Cox; J Hughes; J Daniels; V Azevedo; C McDermid; M Poolman; A Boulle; E Goemaere; G van Cutsem Journal: Int J Tuberc Lung Dis Date: 2014-04 Impact factor: 2.373
Authors: D Falzon; E Jaramillo; H J Schünemann; M Arentz; M Bauer; J Bayona; L Blanc; J A Caminero; C L Daley; C Duncombe; C Fitzpatrick; A Gebhard; H Getahun; M Henkens; T H Holtz; J Keravec; S Keshavjee; A J Khan; R Kulier; V Leimane; C Lienhardt; C Lu; A Mariandyshev; G B Migliori; F Mirzayev; C D Mitnick; P Nunn; G Nwagboniwe; O Oxlade; D Palmero; P Pavlinac; M I Quelapio; M C Raviglione; M L Rich; S Royce; S Rüsch-Gerdes; A Salakaia; R Sarin; D Sculier; F Varaine; M Vitoria; J L Walson; F Wares; K Weyer; R A White; M Zignol Journal: Eur Respir J Date: 2011-08-04 Impact factor: 16.671
Authors: Kathryn Schnippel; Sydney Rosen; Kate Shearer; Neil Martinson; Lawrence Long; Ian Sanne; Ebrahim Variava Journal: Trop Med Int Health Date: 2012-11-21 Impact factor: 2.622
Authors: Florian M Marx; Ted Cohen; Nicolas A Menzies; Joshua A Salomon; Grant Theron; Reza Yaesoubi Journal: Lancet Glob Health Date: 2020-09 Impact factor: 26.763
Authors: Helen Cox; Lebogang Ramma; Lynne Wilkinson; Virginia Azevedo; Edina Sinanovic Journal: Trop Med Int Health Date: 2015-06-01 Impact factor: 2.622
Authors: Jennifer Ho; Anthony L Byrne; Nguyen N Linh; Ernesto Jaramillo; Greg J Fox Journal: Bull World Health Organ Date: 2017-08-01 Impact factor: 9.408